Diane Goéré
Diane Goéré has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Dominique Elias
Department of Surgical Oncology, Gustave Roussy Cancer Campus, Grand Paris, Villejuif Cedex, France
3 shared publications- Maximiliano Gelli
Department of Visceral and Oncological Surgery, Gustave Roussy, Villejuif Cedex, France
3 shared publications - Antonio Sa Cunha
Hepato-Biliary Centre, Paul Brousse, AP-HP, Villejuif, Paris, France
2 shared publications Charles Honoré
Department of Visceral and Oncological Surgery, Gustave Roussy, Cancer Campus, Villejuif Cedex 94805, France
2 shared publications- Charles Honoré
Department of Surgical Oncology, Gustave-Roussy, Villejuif, France
2 shared publications - David Malka
Department of medical oncology, Institut Mutualiste Montsouris, Paris, France
2 shared publications
Latest Publications
- 11 January 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (3) , 852-860
Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry
Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more th
- 11 January 2019
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 26 (3) , 852-860
Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry
Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more th
- Open Access
- 6 August 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 787
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
After curative-intent surgery for colorectal liver metastases (CRLM), liver recurrence occurs in more than 60% of patients, despite the administration of perioperative or adjuvant chemotherapy. This risk is even higher after resection of more than three CRLM. As CRLM are mostly supplied by arterial blood flow, hepatic arterial infusion (HAI) of chemotherapeutic agents after resection of CRLM is an attractive approach. Oxaliplatin-based HAI chemotherapy, in association with systemic fluoropyrimidines, has been shown to be safe and highly active in patients with CRLM. In a retrospective series of 98 patients at high risk of hepatic recurrence (≥4 resected CRLM), adjuvant HAI oxaliplatin combined with systemic chemotherapy was feasible and significantly improved disease-free survival compared to adjuvant, ‘modern’ systemic chemotherapy alone. This study is designed as a multicentre, randomized, phase II/III trial. The first step is a non-comparative randomized phase II trial (power, 95%; one-sided alpha risk, 10%). Patients will be randomly assigned in a 1:1 ratio to adjuvant systemic FOLFOX (control arm) or adjuvant HAI oxaliplatin plus systemic LV5FU2 (experimental arm). A total 114 patients will need to be included. The main objective of this trial is to evaluate the potential survival benefit of adjuvant HAI with oxaliplatin after resection of at least 4 CRLM (primary endpoint: 18-month hepatic recurrence-free survival rate). We also aim to assess the feasibility of delivering at least 4 cycles of HAI (or i.v.) oxaliplatin after surgical treatment of at least 4 CRLM, the toxicity (NCI-CTC v4.0) of adjuvant HAI plus systemic chemotherapy, including HAI catheter-related complications, compared to systemic chemotherapy alone, and the efficacy of adjuvant HAI on hepatic and extra-hepatic recurrence-free (survival and overall survival). If 18-month hepatic recurrence-free survival is greater than 50% in the experimental arm, the study will be pursued in phase III, for which the primary endpoint will be 3-year recurrence-free survival rate. Patients randomized in the phase II will be included in the phase III, with an additional number of 106 patients. ClinicalTrials.gov, NCT02494973 . Trial registration date: July 10, 2015.
- 6 August 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 787
Open AccessPostoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
After curative-intent surgery for colorectal liver metastases (CRLM), liver recurrence occurs in more than 60% of patients, despite the administration of perioperative or adjuvant chemotherapy. This risk is even higher after resection of more than three CRLM. As CRLM are mostly supplied by arterial blood flow, hepatic arterial infusion (HAI) of chemotherapeutic agents after resection of CRLM is an attractive approach. Oxaliplatin-based HAI chemotherapy, in association with systemic fluoropyrimidines, has been shown to be safe and highly active in patients with CRLM. In a retrospective series of 98 patients at high risk of hepatic recurrence (≥4 resected CRLM), adjuvant HAI oxaliplatin combined with systemic chemotherapy was feasible and significantly improved disease-free survival compared to adjuvant, ‘modern’ systemic chemotherapy alone. This study is designed as a multicentre, randomized, phase II/III trial. The first step is a non-comparative randomized phase II trial (power, 95%; one-sided alpha risk, 10%). Patients will be randomly assigned in a 1:1 ratio to adjuvant systemic FOLFOX (control arm) or adjuvant HAI oxaliplatin plus systemic LV5FU2 (experimental arm). A total 114 patients will need to be included. The main objective of this trial is to evaluate the potential survival benefit of adjuvant HAI with oxaliplatin after resection of at least 4 CRLM (primary endpoint: 18-month hepatic recurrence-free survival rate). We also aim to assess the feasibility of delivering at least 4 cycles of HAI (or i.v.) oxaliplatin after surgical treatment of at least 4 CRLM, the toxicity (NCI-CTC v4.0) of adjuvant HAI plus systemic chemotherapy, including HAI catheter-related complications, compared to systemic chemotherapy alone, and the efficacy of adjuvant HAI on hepatic and extra-hepatic recurrence-free (survival and overall survival). If 18-month hepatic recurrence-free survival is greater than 50% in the experimental arm, the study will be pursued in phase III, for which the primary endpoint will be 3-year recurrence-free survival rate. Patients randomized in the phase II will be included in the phase III, with an additional number of 106 patients. ClinicalTrials.gov, NCT02494973 . Trial registration date: July 10, 2015.
- 1 July 2018
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 27 (3) , 563-583
Peritoneal Metastases from Colorectal Cancer
- 1 July 2018
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 27 (3) , 563-583
Peritoneal Metastases from Colorectal Cancer
- 1 December 2016
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (12) , 1630-1631
Treatment of colorectal peritoneal metastases requires multidisciplinary efforts
- 1 December 2016
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (12) , 1630-1631
Treatment of colorectal peritoneal metastases requires multidisciplinary efforts
- 17 December 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 23 (5) , 1618-1624
Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?
This study evaluated the role of surgical debulking in improving pseudomyxoma peritonei (PMP)-related symptoms if complete cytoreductive surgery (CCRS) of huge PMP is unachievable. This was a retrospective analysis of a prospective database of all patients in our tertiary care center treated for PMP between 1992 and 2014. All cases of surgical debulking in patients scheduled for CCRS that proved unachievable during the operation were selected for the present study. Among the 338 patients operated on for PMP, 39 (11.5 %) had undergone surgical debulking because CCRS was unachievable. All of these patients were symptomatic before surgery, and the median PCI was 32 (5-39). More than 80 % of the disease burden was resected in 23 patients (59 %). Mortality and major morbidity rates were 2.5 and 23 %, respectively. After debulking surgery, symptoms gradually subsided over a median time of 23 months and 50 % of the patients no longer experienced PMP-related symptoms after a median follow-up of 24.5 months. After a median follow-up of 46.4 months (range 3-120), median overall (OS) and progression-free (PFS) survival times were 55.5 and 20 months, respectively. Five-year OS and PFS rates were 46 and 11 %, respectively. Aggressive debulking surgery in case of unachievable CCRS for huge PMP can offer prolonged relief of PMP-related symptoms and long-term survival, in experienced centers that are able to be sufficiently aggressive to resect the major part of the disease, and conservative enough to achieve low mortality and good quality of life.
- 17 December 2015
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 23 (5) , 1618-1624
Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?
This study evaluated the role of surgical debulking in improving pseudomyxoma peritonei (PMP)-related symptoms if complete cytoreductive surgery (CCRS) of huge PMP is unachievable. This was a retrospective analysis of a prospective database of all patients in our tertiary care center treated for PMP between 1992 and 2014. All cases of surgical debulking in patients scheduled for CCRS that proved unachievable during the operation were selected for the present study. Among the 338 patients operated on for PMP, 39 (11.5 %) had undergone surgical debulking because CCRS was unachievable. All of these patients were symptomatic before surgery, and the median PCI was 32 (5-39). More than 80 % of the disease burden was resected in 23 patients (59 %). Mortality and major morbidity rates were 2.5 and 23 %, respectively. After debulking surgery, symptoms gradually subsided over a median time of 23 months and 50 % of the patients no longer experienced PMP-related symptoms after a median follow-up of 24.5 months. After a median follow-up of 46.4 months (range 3-120), median overall (OS) and progression-free (PFS) survival times were 55.5 and 20 months, respectively. Five-year OS and PFS rates were 46 and 11 %, respectively. Aggressive debulking surgery in case of unachievable CCRS for huge PMP can offer prolonged relief of PMP-related symptoms and long-term survival, in experienced centers that are able to be sufficiently aggressive to resect the major part of the disease, and conservative enough to achieve low mortality and good quality of life.
- 1 October 2015
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 152 (5) , A26
Récidive après hépatectomie pour métastases hépatiques d’origine colorectale : une analyse du rapport de l’Association française de chirurgie
- 1 October 2015
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 152 (5) , A26
Récidive après hépatectomie pour métastases hépatiques d’origine colorectale : une analyse du rapport de l’Association française de chirurgie
- 17 September 2015
- Published by Springer Nature
- p. 469-475
Selective Hepatic Intra-arterial Chemotherapy
- 17 September 2015
- Published by Springer Nature
- p. 469-475
Selective Hepatic Intra-arterial Chemotherapy
- 1 August 2015
- Published by Elsevier in Journal of Visceral Surgery
- Vol. 152, S8-S13
Parenteral and enteral nutritional support (excluding immunonutrition)
- 1 August 2015
- Published by Elsevier in Journal of Visceral Surgery
- Vol. 152, S8-S13
Parenteral and enteral nutritional support (excluding immunonutrition)
- 10 February 2015
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 11 (2) , 78-83
Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?
- 10 February 2015
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 11 (2) , 78-83
Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?
- 16 April 2014
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 10 (3) , 313-320
Adjuvant HIPEC in Colorectal Cancer
- 16 April 2014
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 10 (3) , 313-320
Adjuvant HIPEC in Colorectal Cancer